Medtronic (MDT) – StreetInsider.com Reports
-
Medtronic, Inc. (MDT) PT Lowered to $88 at Baird
-
Medtronic (MDT) unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care
-
Medtronic (MDT) Sphere-360 PFA catheter demonstrates impressive results in treating paroxysmal atrial fibrillation
-
Medtronic (MDT) Receives FDA Approval of Next-gen Evolut TAVR System
-
Axonics (AXNX) Provides Update on Inter Partes Review Proceedings
-
Medtronic (MDT) Announces US Patent Office Rejected Axonics' Latest Challenge to its patents
-
Axonics, Inc. (AXNX) Responds to ITC Action by Medtronic (MDT)
-
Medtronic (MDT) Files ITC Action Against Axonics to Stop Use of Medtronic Innovations
-
Medtronic, Inc. (MDT) PT Raised to $100 at Stifel
-
Orchestra BioMed (OBIO) Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy f
-
Medtronic, Inc. (MDT) PT Raised to $75 at UBS
-
Medtronic, Inc. (MDT) PT Raised to $92 at Oppenheimer
-
Medtronic, Inc. (MDT) PT Raised to $90 at Truist Securities
-
Medtronic, Inc. (MDT) PT Raised to $98 at Mizuho Securities
-
Medtronic, Inc. (MDT) PT Raised to $90 at Citi
-
Medtronic, Inc. (MDT) PT Lowered to $100 at Evercore ISI
-
Medtronic (MDT) gains after boosting full-year guidance
-
Medtronic (MDT) Tops Q3 EPS by 4c; raises FY24 Guidance
-
Medtronic lifts annual profit forecast, exits ventilator business
-
Medtronic (MDT) to Exit Ventilator Product Line, Reports Q3, Issues Guidance
-
Medtronic (MDT) call put ratio 4.2 calls to 1 put into quarter results
-
Medtronic (MDT) February weekly 85 straddle into quarter results
-
Medtronic, Inc. (MDT) PT Raised to $72 at UBS
-
Medtronic (MDT) Announces FDA approves Percept RC neurostimulator with exclusive BrainSense technology
-
Medtronic (MDT) announces approval for MiniMed 780G System with Simplera Sync disposable
-
Medtronic, Inc. (MDT) PT Raised to $87 at Truist Securities
-
Medtronic shares gain after U.S. FDA approves system for heart conditions
-
Medtronic (MDT) Announces FDA Approval of PulseSelect Pulsed Field Ablation (PFA) System
-
US FDA approves Medtronic's system for heart condition
-
Medtronic, Inc. (MDT) PT Raised to $86 at Citi
-
Medtronic (MDT) and Cosmo to Expand AI Partnership
-
Medtronic (MDT) Declares $0.69 Quarterly Dividend; 3.5% Yield
-
Medtronic (MDT) terminates deal to acquire EOFlow
-
Medtronic, Inc. (MDT) PT Lowered to $79 at Deutsche Bank
-
Medtronic, Inc. (MDT) PT Lowered to $98 at Morgan Stanley
-
Medtronic, Inc. (MDT) PT Raised to $82 at JPMorgan
-
Medtronic, Inc. (MDT) PT Raised to $84 at Truist Securities
-
Medtronic, Inc. (MDT) PT Raised to $84 at Baird
-
Midday movers: Agilent, VMware, Lowe’s and more
-
Medtronic lifts annual outlook following "broad-based" demand for medical devices
-
Medtronic shrugs off concerns over newer weight-loss drugs, raises annual forecast
-
Medtronic (MDT) Tops Q2 EPS by 7c, Beats on Revenue; Raises EPS Guidance
-
Medtronic (MDT) November weekly option implied volatility into quarter results
-
Dow Jones, Nasdaq, S&P 500 weekly preview: Nvidia to report
-
Medtronic (MDT) Announces FDA Approval of Minimally Invasive Device to Treat Hypertension
-
Medtronic (MDT) November weekly 75 straddle into quarter results
-
Medical Devise Stocks Gain on Better Than Feared Wegovy Data
-
Medtronic (MDT) receives FDA approval for extravascular defibrillator to treat abnormal heart rhythms, sudden cardiac arrest
-
Medtronic, Inc. (MDT) PT Lowered to $90 at Mizuho Securities
-
Medtronic, Inc. (MDT) PT Lowered to $77 at Baird
Back to MDT Stock Lookup